BEVERLY HILLS, CA / ACCESS Newswire / July 18, 2025 / World-renowned spinal neurosurgeon and motion preservation expert Dr.

Emerging Degenerative Disc Disease therapies in the different phases of clinical trials are-SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and ...

The field of gerontology is witnessing a significant demographic transition, as the global population of individuals aged 65 ...

"FDA approves Dymicron’s study of cervical artificial disc" was originally created and published by Medical Device Network, a ...

According to Credence Research, the global Spine Degenerative Disk Disease Treatment Market was valued at USD 22,272.2 ...

Degenerative disc disease (DDD) and intervertebral disc degeneration (IVDD) represent conditions that impair the function of the spinal motion segments, profoundly affecting quality of life worldwide.

Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced that the United ...

A new study published in the journal of Arthritis Care and Research revelaed that metabolic syndrome is associated with ...

Dymicron’s Triadyme-C artificial disc earned the FDA’s investigational device exemption approval, according to a July 10 news release. The IDE approval opens the door for a U.S. trial of the disc, ...

RICHMOND, Virginia () — Dozens of people have contacted CBS 6 offering to help a 70-year-old woman with a degenerative disc disease who needs assistance picking up a motorized wheelchair.“I ...